Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Fangzhou expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%
-
Fangzhou plans to allocate approximately 90% of the net proceeds to accelerate development of the Company's AI-driven chronic disease management platform.
-
Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution.
-
Fangzhou was recognized with the “Social Responsibility Golden Bull Award”.
-
Fangzhou was presented with a Generative AI Service Filing Certificate at the first Guangdong Provincial LLM Filing Conference.
-
Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition
-
Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration.
-
Fangzhou's “XingShi” Large Language Model (“XS LLM”) was featured by Nature News.
-
was recognized as an “Outstanding Growth Story in Hong Kong Stocks”
-
Fangzhou announced the release of its proprietary “XingShi” Large Language Model.